A sharp decline in U.S. overdose deaths appears increasingly tied to a disruption in the global fentanyl supply chain – an outcome that new research suggests may stem in part from intensified pressure on Chinese chemical suppliers.
The findings, published Thursday in Science, enter a long-running debate over what finally reversed a drug crisis that pushed annual overdose deaths above 100,000 during the Biden administration. Fatalities began falling in mid-2023 and dropped more sharply thereafter, a trend that has continued under Donald Trump, who has long-framed fentanyl trafficking as a national-security threat and used tariffs, border enforcement and overseas interdictions as leverage.
While public-health officials have pointed to billions spent on addiction treatment, naloxone distribution and domestic law enforcement, the research places renewed emphasis on a crackdown by Beijing – specifically, efforts to prevent fentanyl from being manufactured at all.
The paper concludes that the illicit fentanyl market experienced a significant supply contraction, “possibly tied to Chinese government actions,” citing falling purity in seized drugs, reduced seizure volumes and online reports of shortages. The findings align with arguments long advanced by Trump and his advisers: that pressuring China’s chemical sector was central to choking off supply.
“This demonstrates how influential China can be and how much they can help us – or hurt us,” said Keith Humphreys, a co-author of the study and a former White House drug policy adviser under President Barack Obama.
U.S. law-enforcement agencies have for years scrutinized China’s role as a key supplier of precursor chemicals used by Mexican criminal organizations to synthesize fentanyl. During Trump’s first term, Beijing agreed to classify fentanyl-related substances, though traffickers adapted by shifting to precursor chemicals instead.
Since 2023, however, Chinese authorities have shut down some chemical suppliers and tightened oversight. The Drug Enforcement Administration, in its latest annual drug intelligence report, said China-based suppliers are increasingly wary of selling internationally – evidence, the agency said, that enforcement pressure is having an effect.
According to the CDC, estimated U.S. drug deaths fell in 2024 to about 81,700, with roughly 49,200 involving synthetic opioids such as fentanyl. While 2025 data are not yet available, researchers believe the downward trend is continuing.
The timing remains contested. Formal U.S. – China cooperation was announced ahead of a November 2023 summit between Joe Biden and Xi Jinping, months after overdose deaths had already begun to fall. Researchers acknowledge the mismatch but suggest Chinese enforcement may have begun quietly before the agreement was made public.
You must be logged in to post a comment.